Empagliflozin (Jardiance)

About Boehringer Ingelheim

Boehringer Ingelheim is a major, privately-held German pharmaceutical powerhouse with a significant global footprint in human and animal health. Its strategy is built on deep research expertise across multiple therapeutic modalities, including immunology, cardiometabolic diseases, and oncology. The company maintains a robust pipeline and invests heavily in R&D, supported by a stable financial position due to its private ownership structure. Its key challenges include navigating intense therapeutic area competition and the inherent risks of late-stage clinical development.

Therapeutic Areas